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Clinical Investigation
Stability of Extemporaneously Prepared Lansoprazole Suspension at 
Two Temperatures
 
Jordan T. Morrison, PharmD,1 Ralph A. Lugo, PharmD,2 Jim C. Thigpen, PharmD,2 and Stacy D. Brown, PhD1
Departments of 1Pharmaceutical Sciences and 2Pharmacy Practice, East Tennessee State University, Johnson City, 
Tennessee
OBJECTIVE  The purpose of this study was to examine the stability of a generic lansoprazole product in a 3 
mg/mL sodium bicarbonate suspension under room temperature and refrigerated conditions.
METHODS  Lansoprazole suspensions (3 mg/mL) were prepared in triplicate using an 8.4% sodium bicarbon-
ate vehicle for each storage condition (room temperature and refrigerated). During 1 month, samples from 
each replicate were periodically removed and analyzed for lansoprazole concentration by liquid chromatog-
raphy–tandem mass spectrometry (LC-MS/MS). Each sample was spiked with 10 mg/L omeprazole to serve 
as the internal standard. A positive electrospray LC-MS/MS method was validated over the calibration range 
of 5 to 25 mg/L using Food and Drug Administration Guidance. The identities of the analyte and internal 
standard in the samples were verified by monitoring the MS/MS transitions of m/z 370 to m/z 252 and m/z 
346 to m/z 198 for lansoprazole and omeprazole, respectively. Additionally, the pH of the suspensions was 
monitored throughout the study.
RESULTS  The stability of lansoprazole in the oral sodium bicarbonate suspension under refrigeration is com-
promised prior to what has been previously reported in the literature. Samples kept at room temperature lost 
>10% of the lansoprazole after 48 hours compared with the refrigerated samples, which maintained integrity 
up to 7 days. No statistically significant difference was found between the pH of the room temperature and 
refrigerated suspension samples, indicating that this factor is not the cause for the differences in stability 
at these two conditions.
CONCLUSIONS  This study suggests that the extemporaneously compounded lansoprazole oral suspension 
prepared in 8.4% sodium bicarbonate should not be stored in plastic oral syringes longer than 48 hours at 
room temperature and no longer than 7 days when refrigerated. These data indicate an expiration time 
earlier than that previously reported for the refrigerated product (14 days).
INDEX TERMS  drug stability, lansoprazole, suspensions
J Pediatr Pharmacol Ther 2013;18(2):122–127
INTRODUCTION
Proton pump inhibitors (PPIs) are medications 
that decrease the amount of acid produced by 
gastric parietal cells via the inhibition of the H+/
K+ ATPase enzyme system. Uses for this class 
include gastroesophageal reflux disease, preven-
tion of stress-induced ulcers, and treatment of 
Barrett esophagus, in adults. Lansoprazole has an 
indication for treating pediatric patients (ages 1-11 
years) but lacks established safety or effectiveness 
data for children younger than 1 year. Even with-
out the data for use in the neonatal population, 
PPI use has become routine. The North American 
Society for Pediatric Gastroenterology, Hepatol-
ogy and Nutrition and the European Society for 
Pediatric Gastroenterology, Hepatology, and Nu-
trition recommend the use of PPIs in neonates (>3 
days and without complications) for the treatment 
of gastroesophageal reflux.1
Aside from the dearth of safety and effective-
ness information, another obstacle in using PPIs 
in neonatal and pediatric patients is the vehicle 
of administration. Commonly, adults using PPIs 
will receive the medication in a capsule form, but 
this is not always practical for younger patients. 
Suspensions are often used in these populations 
for PPI administration. In a prospective study 
performed by Lugo et al,2 that included 21 chil-
dren’s hospitals, an oral suspension of lansopra-
JPPT
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zole was the number one reported extemporane-
ous formulation prepared in the inpatient setting. 
In the study, 19 of 21 hospitals surveyed reported 
using a 3 mg/mL lansoprazole oral suspension; 
however, there are limited data regarding the 
stability of this formulation.2
Olabisi et al3 examined preparations of lan-
soprazole for nasogastric tube administration. 
The study included lansoprazole mixed with a 
variety of vehicles, including apple juice, cran-
berry juice, ginger ale, orange juice, water, and 
sodium bicarbonate 8.4%. The suspensions were 
then passed through a nasogastric (NG) tube and 
collected in a graduated cylinder. Of all of the 
tested vehicles, sodium bicarbonate 8.4% was 
the only one found to provide complete drug re-
trieval after administration through the NG tube. 
Lansoprazole mixed with sodium bicarbonate 
8.4% was also the only tested combination that 
did not result in any clogging in the NG tube, but 
despite this, the manufacturer still recommends 
the use of apple juice for NG tube administra-
tion of Prevacid.3,4 An alternative formulation 
of lansoprazole in Ora-Blend has been recently 
proposed by Melkoumov et al,5 yet the stability 
is limited to 3 days under refrigeration.
Preparing lansoprazole suspension in the 8.4% 
sodium bicarbonate vehicle, known as simplified 
lansoprazole suspension (SLS), is the historical 
standard6; however, studies examining the sta-
bility of the drug in this basic suspension are 
conflicting. According to a study by DiGiacinto 
et al,7 the reported stability of lansoprazole sus-
pension was 8 hours at 22°C and 14 days at 4°C. 
In contrast, a study performed by Phillips et al8 
revealed a stability of 4 weeks when lansoprazole 
was stored in amber plastic vials under refrig-
eration and 2 weeks at room temperature. Thus, 
the commonly accepted stability of lansoprazole 
suspension prepared in 8.4% sodium bicarbon-
ate is 14 days if kept refrigerated.9 The objective 
of this study was to verify the stability (NLT 
90% and NTM 110% of the labeled amount)10 




Previously published ultra-high-pressure liquid 
chromatography–tandem mass spectrometry 
methodology was used to analyze all stability 
study samples for lansoprazole concentration.11 
This method was developed and validated ac-
cording to Food and Drug Administration guide-
lines for bioanalytical methods.12,13 During each 
day of the study, fresh calibration standards using 
USP reference standards were prepared in 50:50 
v/v water-methanol mixture. The calibration 
curve consisted of 5 points: 5, 10, 15, 20, and 25 
mg/L lansoprazole. Each calibration and valida-
tion solution contained 10 mg/L omeprazole. The 
calibration curves used in the study displayed 
a linear response in the aforementioned range 
with a slope of 0.08596 ± 0.00709, a y-intercept of 
0.3525 ± 0.0429, and an R2 value of 0.9931 ± 0.0284. 
Quantification was performed using the peak area 
ratios between lansoprazole and omeprazole.
Stability Study 
Lansoprazole suspension (3 mg/mL) was pre-
pared in triplicate for both refrigerated (3ºC-4oC) 
and room temperature (20ºC-22ºC) storage. The 
suspensions were made by emptying the contents 
of ten 30-mg generic capsules of lansoprazole into 
an Erlenmeyer flask and adding 100 mL of 8.4% 
sodium bicarbonate solution. The suspensions 
were then stirred on a magnetic stir plate for 30 
minutes and protected from light. Following this, 
the density of each bulk preparation at room tem-
perature was determined using 10-mL samples 
in a 10-mL graduate cylinder. This 10-mL sample 
of each was retained for baseline pH determina-
tion. Thereafter, 0.6-mL aliquots of suspension 
were drawn up into plastic amber-colored oral 
syringes to be stored under the 2 test conditions. 
Syringes were removed for each time point, the 
contents were diluted with 8.4 mL of a 50:50 mix 
of methanol and water, and they were vortex 
mixed. From this mixture, 100 µL was removed 
by micropipette and further diluted with 800 µL 
of the 50:50 solvent mixture. A volume of 100 µL of 
the internal standard (100 mg/L omeprazole) was 
added to the aforementioned mixture for a final 
concentration of 10 mg/L omeprazole. The final 
dilution of lansoprazole was intended to bring 
the sample concentration within the calibration 
range (5-25 mg/L). The actual concentration of 
lansoprazole in each sample was calculated using 
the calibration curve from that day. Suspension 
samples were filtered via a 0.22-µm filter prior to 
being added to the autosampler vials.
For each sampling time point, the filled and 
empty syringes were weighed so as to correct for 
Extemporaneously Prepared Lansoprazole
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density differences between the replicate prepa-
rations. This strategy of using the weight of the 
suspension sample instead of the volume alone 
has been previously demonstrated as an effective 
way to compensate for the error involved in sam-
pling a non-homogeneous matrix.14 At each time 
point, 2 samples were taken from each replicate, 
and each sample was injected twice for a total of 4 
injections at each time point. Additional samples 
were analyzed from the bulk suspensions at time 
0 hours and at 7, 14, and 30 days to assess the 
impact of storage in the oral syringes. Finally, 
the pH of the preparations was monitored at 0 
hours and at 7, 14, 21, and 30 days.
Data Analysis 
The stability of lansoprazole in the oral suspen-
sion preparations was assessed by comparing 
the percentage of drug remaining at each time 
point to the initial concentration. Statistical 
analyses were performed using GraphPad Prism 
software (GraphPad Software, La Jolla, CA). Ad-
ditionally, 1-way analysis of variance (ANOVA; 
p<0.05) with a Dunnett posttest was used to 
verify statistically significant degradation. The 
degradation constant (k) was determined from 
linear regression data of each replicate, assum-
ing first-order kinetics, because the first-order 
degradation model fit the data better than zero 
or second order. Using the degradation constants 
from each temperature condition, the frequency 
factor and activation energy of degradation were 
calculated using the Arrhenius equation.8 Ad-
ditional analyses included verification that the 
replicates within each temperature condition 
were not statistically different using a repeated-
measures ANOVA (p<0.05) and a Bonferroni 
posttest. The pH measurements between the 2 
conditions were also compared using a 2-tailed 
Student t-test (p<0.05). Finally, to evaluate the im-
pact of storing the samples in oral syringes versus 
the bulk suspension, these data were compared 
using a 1-way ANOVA with Bonferroni multiple 
comparison test (p<0.05).
RESULTS
Room Temperature Samples Versus Refrigerated 
Samples
The Table shows the degradation profiles of 
the lansoprazole suspensions at refrigerated and 
room temperature conditions. Under refrigera-
tion, the drug concentration in the suspension 
first dipped below 90% at the 8-day time point, 
and at 72 hours for room temperature samples. 
This indicates a beyond-use date of 7 days (re-
frigerated) and 48 hours (room temperature) 
for SLS prepared with generic lansoprazole. 
Statistically significant degradation was verified 
using the 1-way ANOVA analysis (p<0.05; 0-hour 
concentration as control). Additionally, within 
each experimental group the replicates were 
not shown to have any statistically significant 
differences. Statistically significant pairing was 
noted in both groups, with R2 = 0.9293 in the 
refrigerated group and R2 = 0.8794 among the 
room temperature replicates.
Degradation Kinetics
Various concentration-versus-time plots were 
examined for the combination of replicates from 
each condition, and it was determined that 
first-order kinetics was the best fit. Using the 
degradation rate constant (k) for each replicate at 
each condition, the frequency factor (A) and the 
activation energy (Ea) were determined from the 
Arrhenius equation, resulting in A = 17,354 hr−1 
and Ea = 26.5 kJ/mol. The mean rate constants 
Table. Stability of Lansoprazole up to 90 Days at Room Temperature (20ºC -22ºC) and Refrigerated Temperature (3ºC-
4ºC) Expressed as Mean Concentration (mg/mL) ± SD and Percent Remaining From Initial Concentration (Time 0 Hours), 
n=12, for Each Condition at Each Time Point, Determined by LC-MS/MS Using Omeprazole as an Internal Standard*
Storage Time Since Compounding
0 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 48 hr
20ºC-22ºC 2.70 ± 0.23, 
100
2.60 ± 0.14, 
96.0




2.45 ± 0.25, 
90.7
2.49 ± 0.24, 
92.2
2.47 ± 0.28, 
91.2
2.45 ± 0.28, 
90.8
3ºC-4ºC 2.82 ± 0.16, 
100
2.78 ± 0.30, 
98.6
2.78 ± 0.12, 
99.1
2.74 ± 0.40, 
97.1
2.71 ± 0.11, 
96.1
2.68 ± 0.16, 
95.0
2.67 ± 0.14, 
94.6
2.65 ± 0.14, 
94.0
*Values given are displayed as: mean lansoprazole concentration (mg/mL) ± SD, percent deviation from initial concentration (concentra-
tion at time 0 hours)
JT Morrison, et al
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for the refrigerated replicate were 0.000187 and 
0.000179 hr−1 for the samples stored under room 
temperature.
Stability of pH
Sample pH was periodically monitored 
throughout the study. Refrigerated samples held 
a pH of 8.579 ± 0.118 (average ± SD; n=15), where-
as the room temperature sample pH was 8.578 
± 0.127 (n=15). No statistically significant differ-
ence in these data was detected using a 2-tailed 
Student t-test (p<0.05) with an R2 of 3.294e-005, 
and the relative SD of these measurements was 
less than 1.5% for each group. This indicates that 
pH was not a factor in the drug degradation and 
that the 8.4% sodium bicarbonate was sufficient 
to maintain pH past the beyond-use time for both 
temperature conditions.
Impact of Density Correction 
Using a density correction to compensate for 
sampling from a non-homogeneous mixture 
has been shown to be effective in previous 
studies on omeprazole stability.14 The error that 
is compensated for by this density correction 
ranges from 0.82% to 17.3%, with a 6.95% mean 
deviation between the data that were corrected 
for the weight/density of the sample versus 
that which were not. The replicates that were 
refrigerated had a density of 1.073 ± 0.054 (mean 
± SD; n = 3), and the room temperature ones had 
a density of 1.033 ± 0.0052 (n=3). Furthermore, 
the densities of these 2 groups of preparations 
were compared using an unpaired, 2-tailed t-test, 
and the means were not found to be statistically 
different (p<0.05).
Impact of Storage in Syringes Versus Bulk Bottles 
Finally, the results from the suspension sam-
ples stored in amber syringes were compared 
with a limited number of sampling points from 
the bulk (amber-colored) plastic bottles of each 
replicate. The calculated concentration of lanso-
prazole at 168-, 336-, and 720-hour time points 
was compared between the bulk bottles and 
corresponding oral syringes for each replicate; 
however, no statistically significant difference 
was detected (p<0.05).
DISCUSSION
Use of Liquid Chromatography–Tandem Mass 
Spectrometry Technology to Study Drug Stability 
Most published drug stability studies use 
high-performance liquid chromatography with 
ultraviolet detection for quantification of the 
drug of interest. In this study, we employed a 
more sensitive and specific methodology, liquid 
chromatography–tandem mass spectrometry 
(LC-MS/MS), because of the concerns regarding 
rapid degradation of lansoprazole. Unlike ultra-
violet detection, mass spectrometric detection 
correlates to the specific molecular weight of a 
compound, and with our instrument this molecu-
lar weight is accurate out to 0.0001 mass units. 
This specificity ensures that the chromatographic 
peak being monitored is in fact that of the drug 
of interest—in this case lansoprazole—and not 
a degradation product. Specificity is ensured by 
monitoring an ion channel specific to the molecu-
lar weight of lansoprazole (m/z 370).
Density Correction in Data Analysis
The impact of our correcting for the mass 
of each of the samples in this study cannot be 
overstated. When samples from this non-homo-
geneous suspension are removed by volume, 
even with a wide-opening pipette tip, their in-
dividual contents can vary greatly. Rather than 
relying on pipette volume to calculate lansopra-
Table. Stability of Lansoprazole up to 90 Days at Room Temperature (20ºC -22ºC) and Refrigerated Temperature (3ºC-
4ºC) Expressed as Mean Concentration (mg/mL) ± SD and Percent Remaining From Initial Concentration (Time 0 Hours), 
n=12, for Each Condition at Each Time Point, Determined by LC-MS/MS Using Omeprazole as an Internal Standard* (cont.)
Storage Time Since Compounding
72 hr 96 hr 7 days 8 days 14 days 21 days 30 days
20ºC-22ºC 2.37 ± 0.17, 
87.7




2.34 ± 0.30, 
86.6
2.37 ± 0.07, 
87.8
2.27 ± 0.17, 
84.1
2.27 ± 0.25, 
83.8
3ºC-4ºC 2.63 ± 0.29, 
93.1




2.50 ± 0.18, 
88.5
2.53 ± 0.26, 
89.8
2.46 ± 0.18, 
87.2
2.43 ± 0.17, 
86.0
*Values given are displayed as: mean lansoprazole concentration (mg/mL) ± SD, percent deviation from initial concentration (concentra-
tion at time 0 hours)
Extemporaneously Prepared Lansoprazole
JPPT
126 J Pediatr Pharmacol Ther 2013 Vol. 18 No. 2 • www.jppt.org
zole concentration in the samples, we used the 
sample weight and determined the true volume 
withdrawn using density of each replicate. The 
precedent for this practice has been set,14 and we 
found it to be an effective way to compensate 
for sampling from non-homogeneous mixtures. 
This also removes the need for timed shaking for 
resuspension prior to sampling.
Initial Lansoprazole Concentration 
The recipe used for compounding SLS reports 
an initial concentration of 3 mg/mL, which is 
expected following complete release of drug from 
polymer microspheres and 100% dissolution if 
300 mg of drug were dissolved in 100 mL of ve-
hicle. However, previous studies have indicated 
limitations in the dissolution of lansoprazole in 
sodium bicarbonate, suggesting that Ora-Blend 
may be a more suitable vehicle for this prepara-
tion.5 Because of this, we determined an initial, 
time-0 hours, concentration of each replicate to 
serve as the reference against which the beyond-
use date was calculated. This practice is common 
in stability investigations because this starting 
concentration will vary slightly among individual 
preparations.15–18 Nevertheless, our preparations 
recovered a mean of 90.3% (room temperature 
replicates) and 94.2% (refrigerated replicates) rela-
tive to the theoretical concentration of 3 mg/mL.
Directions for Future Stability Investigations 
Work by Ensom et al19 indicates the stability of 
lansoprazole in oral suspension can be retained 
up to 90 days if stored in glass containers. In this 
study, they also address the important issue of 
not only a stable preparation, but also a palatable 
one, showing that the traditional SLS is highly 
undesirable for oral administration, restricting 
its use to NG administration.19 Future investiga-
tion is called for that looks at the interactions 
this drug has with plastic matrices, with regard 
to storage in plastic prescription bottles, in oral 
syringes, and administration through NG tubes. 
Additionally, the practice of reserving all stability 
study samples at −80oC so they can be analyzed 
on the same day has the potential to reduce error 
associated with intraday variations.19
CONCLUSION
The results of this study indicate that lanso-
prazole suspension (3 mg/mL) loses stability, 
as defined by >10% reduction of the initial con-
centration, at 48 hours under room temperature 
conditions and after 7 days under refrigerated 
conditions. These study samples were stored in 
amber-colored oral syringes to protect the drug 
from light as well as to ensure ease of sampling 
during the study. The results of this study indi-
cate that the stability of lansoprazole suspension 
under refrigeration is shorter than previously 
recognized, if stored in plastic oral syringes. 
However, this study shows that the 8.4% sodium 
bicarbonate vehicle is sufficient to maintain the 
pH of this drug preparation past the beyond-
use time, and that storage in amber-colored oral 
syringes results in stability comparable to that 
of storage in bulk amber-colored plastic bottles, 
regardless of temperature. Suspension palatabil-
ity was not assessed. Finally, the use of density 
correction to account for differences among non-
homogeneous preparations such as SLS allows 
for more accurate quantification of the drug in 
small sample volumes.
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